Oil emulsions as vaccine adjuvants

Novel Immunologic Adjuvants

Volumn , Issue , 2011, Pages 29-40

  Haensler, Jean ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865747851     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.11.17     Document Type: Chapter

References (22)

1. Ott G, Van Nest G. Development of vaccine adjuvants: a historical perspective. In: Vaccine Adjuvants and Delivery Systems Singh M (Ed.). John Wiley & Sons, NJ, USA, 1-31 (2007).
2. Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14, 3286-3312 (2009).
3. Chang JCC, Diveley JP, Savary JR, Jensen FC. Adjuvant activity of inconpletes Freund's adjuvant. Adv. Drug Del. Rev. 32, 173-186 (1998).
4. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev. Vaccines 8(4), 483-492 (2009).
5. Aucouturier J, Dupuis L, Deville S, Ganne V. Montanide ISA720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1(11), 111-118 (2002).
6. Iseki K, Matsunaga H, Komatsu N et al. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci. 101(10), 2110-2114 (2010).
7. Simon JK, Edelman R. Clinical evaluation of adjuvants. In: Immunopotentiators in Modern Vaccines. Schijns V, O'Hagan D (Eds). Elsevier, Amsterdam, The Netherlands 319-342 (2005).
8. Rodríguez P.C., Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAVax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 12(1), 17-23 (2010).
9. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther. 82(6), 740-744 (2007).
10. O'Hagan DT, Tsai T, Reed S. Emulsion-based adjuvants for improved influenza vaccines. In: Influenza Vaccines for the Future (2nd Edition) Del Giudice G, Rappuoli R (Eds). Springer Basel, Switzerland 327-352 (2011).
11. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563-571 (2009).
12. Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P. Safety review: squalene and thimerosal in vaccines. Thérapie 65(6), 533-541 (2010).
13. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10(4), 471-486 (2011).
14. Chakravarty J, Kumar S, Trivedi S et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29(19), 3531-3537 (2011).
15. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int. Review Immunol. 30, 150-182 (2011).
16. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 27(25-26), 3331-3334 (2009).
17. Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13), 2461-2473 (2011).
18. Kalvodova L. Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. Biochem. Biophys. Res. Commun. 393(3), 350-355 (2010).
19. Yang YW, Wu CA, Morrow WJW. Cell death induced by vaccine adjuvants containing surfactants. Vaccine 22, 1524-1536 (2004).
20. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8(4), 279-289 (2008).
21. European Medicines Agency www.ema.europa.eu
22. Clinical trials database www.clinicaltrials.gov